Skip to main content
Midas Edge

Definium Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 9, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 9, 2026

DFTX$34.64-2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Shareholders' Equity

Common Shares · Additional Paid-In Capital · Accumulated Other Comprehensive Income (Loss)
(in thousands, except share amounts) · Shares · Amount · Accumulated Deficit · Total
Balance, December 31, 202598,776,265$—$913,914$1,085$(582,672)$332,327
Issuance of common shares under ESPP33,787—276——276
Issuance of common shares upon settlement of restricted share unit ("RSU") awards169,306—————
Exercise of 2022 USD Financing Warrants901,800—15,313——15,313
Exercise of pre-funded warrants4,000,000—4——4
Amortization of deferred ATM costs——(40)——(40)
Stock-based compensation expense——7,132——7,132
Exercise of stock options163,350—1,196——1,196
Net loss and comprehensive loss———(261)(77,098)(77,359)
Balance, March 31, 2026104,044,508$—$937,795$824$(659,770)$278,849
Issuance of common shares, net of shares issuance cost23,676,471—758,730——758,730
Issuance of common shares upon conversion of term loan principal594,016—4,500——4,500
Issuance of common shares upon settlement of RSU awards293,055—————
Exercise of 2022 USD Financing Warrants669,895—25,532——25,532
Exercise of pre-funded warrants5,018,775—5——5
Amortization of deferred ATM costs——(42)——(42)
Stock-based compensation expense——9,639——9,639
Exercise of stock options69,230—859——859
Net loss and comprehensive loss———(407)(158,986)(159,393)
Balance, June 30, 2026134,365,950$—$1,737,018$417$(818,756)$918,679
Issuance of common shares under ESPP32,520—467——467
Issuance of common shares upon settlement of RSU awards340,659—————
Exercise of 2022 USD Financing Warrants2,001,000—87,843——87,843
Amortization of deferred ATM costs——(41)——(41)
Stock-based compensation expense——10,775——10,775
Exercise of stock options, net of shares withheld for exercise and tax147,428—2,518——2,518
Net loss and comprehensive loss———(1,246)(50,961)(52,207)
Balance, September 30, 2026136,887,557$—$1,838,580$(829)$(869,717)$968,034
Balance, December 31, 202475,100,763$—$639,508$819$(398,879)$241,448
Issuance of common shares under ESPP34,017—186——186
Issuance of common shares upon settlement of RSU awards186,708—————
Exercise of 2022 USD Financing Warrants136,346—874——874
Stock-based compensation expense——3,426——3,426
Exercise of stock options53,541—237——237
Net loss and comprehensive loss———(17)(23,348)(23,365)
Balance, March 31, 202575,511,375$—$644,231$802$(422,227)$222,806
Issuance of common shares upon settlement of RSU awards229,587—————
Stock-based compensation expense——5,253——5,253
Exercise of stock options, net of shares withheld for exercise and tax62,289—80——80
Net loss and comprehensive loss———5(42,744)(42,739)
Balance, June 30, 202575,803,251$—$649,564$807$(464,971)$185,400
Issuance of common shares under ESPP32,148—226——226
Issuance of common shares upon settlement of RSU awards221,863—————
Exercise of 2022 USD Financing Warrants450,000—5,127——5,127
Issuance of common shares upon conversion of loan principal249,377—1,000——1,000
Stock-based compensation expense——5,816——5,816
Exercise of stock options, net of shares withheld for exercise and tax17,418—98——98
Net loss and comprehensive loss———194(67,265)(67,071)
Balance, September 30, 202576,774,057$—$661,831$1,001$(532,236)$130,596
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.